Pursuant to clause 8 of the COVID-19 Public Health Response (Point-of-care Tests) Order 2021 (“Order”), I, Dr Ashley Bloomfield, the Director-General of Health, being satisfied that:

1. the activities authorised in this notice will not pose a material risk to the public health response to COVID-19; and
2. the authorisation is not inconsistent with the purpose of the Act; and
3. the authorisation is no broader than is reasonably necessary to address the matters giving rise to it.

authorise the persons and classes of persons listed in Schedule 1 of this notice to import, supply, sell, distribute or use the molecular point of care test devices listed in Schedule 2 of this notice.

Schedule 1: Persons Authorised Under This Notice

Persons and classes of persons authorised under this notice are:

1. All laboratories accredited by International Accreditation New Zealand (IANZ) to ISO 15189 for COVID-19 testing;
2. All District Health Boards established by section 19 of the New Zealand Public Health and Disability Act 2000;
3. All NZ District Health Board hospitals certified under the Health and Disability Services (Safety) Act 2001 to provide hospital care, as defined in section 4 of that Act;
4. New Zealand Clinical Research (NZCR);
5. Medical suppliers and distributors importing tests listed in Schedule 2 for the sole purpose of supply, sale or distribution of the tests directly to District Health Boards or an IANZ ISO 15189 accredited laboratory.

Schedule 2: Tests Permitted to be Imported, Supplied, Sold, Distributed or Used by Authorised Persons

Dated at Wellington this 3rd day of March 2022.

Dr ASHLEY BLOOMFIELD, Director-General of Health.